<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Addiction</journal-id><journal-id journal-id-type="iso-abbrev">Addiction</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Addiction (Abingdon, England)</journal-title></journal-title-group><issn pub-type="ppub">0965-2140</issn><issn pub-type="epub">1360-0443</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11908935</article-id><article-id pub-id-type="pmcid-ver">PMC11908935.1</article-id><article-id pub-id-type="pmcaid">11908935</article-id><article-id pub-id-type="pmcaiid">11908935</article-id><article-id pub-id-type="manuscript-id">NIHMS2037080</article-id><article-id pub-id-type="pmid">39552271</article-id><article-id pub-id-type="doi">10.1111/add.16715</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS2037080</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA2037080</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Artificial intelligence-based drug repurposing with electronic health record clinical corroboration: a case for ketamine as a potential treatment for amphetamine-type stimulant use disorder</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Gao</surname><given-names initials="Z">Zhenxiang</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Winhusen</surname><given-names initials="TJ">T. John</given-names></name><xref rid="A2" ref-type="aff">2</xref><xref rid="CR1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gorenflo</surname><given-names initials="MP">Maria P.</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dorney</surname><given-names initials="I">Ian</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ghitza</surname><given-names initials="UE">Udi E.</given-names></name><xref rid="A5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kaelber</surname><given-names initials="DC">David C.</given-names></name><xref rid="A6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xu</surname><given-names initials="R">Rong</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="CR1" ref-type="corresp">*</xref></contrib></contrib-group><aff id="A1"><label>1.</label>Center for Artificial Intelligence in Drug Discovery, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.</aff><aff id="A2"><label>2.</label>Center for Addiction Research, University of Cincinnati College of Medicine, Cincinnati, OH, USA.</aff><aff id="A3"><label>3.</label>Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.</aff><aff id="A4"><label>4.</label>School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.</aff><aff id="A5"><label>5.</label>Center for the Clinical Trials Network (CCTN), National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), Bethesda, MD, USA.</aff><aff id="A6"><label>6.</label>Center for Clinical Informatics Research and Education, The Metro Health System, Cleveland, Ohio, USA.</aff><author-notes><fn fn-type="con" id="FN1"><p id="P1">Authorship contribution statement</p><p id="P2">RX conceived, designed, and supervised the study. ZG performed AI model design, clinical evaluation and the mechanism of action study. RX, ZG, MG, ID drafted the manuscript. TJW, UEG, and DCK critically contributed to data interpretation and result discussion. All authors approved the manuscript.</p></fn><corresp id="CR1"><label>*</label>Corresponding to: Center for Artificial Intelligence in Drug Discovery, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA., <email>rxx@case.edu</email> (Rong Xu), Center for Addiction Research, University of Cincinnati College of Medicine, Cincinnati, OH, USA., <email>winhust@ucmail.uc.edu</email> (T. John Winhusen).</corresp><fn fn-type="COI-statement" id="FN2"><p id="P32">Declaration of Competing Interest</p><p id="P33">The authors declare that they have no conflict of interest.</p></fn></author-notes><pub-date pub-type="ppub"><month>4</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>17</day><month>11</month><year>2024</year></pub-date><volume>120</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">484261</issue-id><fpage>732</fpage><lpage>744</lpage><pub-history><event event-type="nihms-submitted"><date><day>09</day><month>12</month><year>2024</year></date></event><event event-type="pmc-release"><date><day>01</day><month>04</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-03-15 16:25:31.647"><day>15</day><month>03</month><year>2025</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-2037080.pdf"/><abstract id="ABS1"><sec id="S1"><title>Background and aims:</title><p id="P3">Amphetamine-type stimulants are the second most used illicit drugs globally, yet there are no US Food and Drug Administration (FDA)-approved treatments for amphetamine-type stimulant use disorders (ATSUD). The aim of this study was to utilize a drug discovery framework that integrates artificial intelligence (AI)-based drug prediction, clinical corroboration, and mechanism of action analysis to identify FDA-approved drugs that can be repurposed for treating ATSUD.</p></sec><sec id="S2"><title>Design and setting:</title><p id="P4">An AI-based knowledge graph model was first utilized to prioritize FDA-approved drugs in their potential efficacy for treating ATSUD. Among the top 10 ranked candidate drugs, ketamine represented a novel candidate with few studies examining its effects on ATSUD. We therefore conducted a retrospective cohort study to assess the association between ketamine and ATSUD remission using U.S. electronic health record (EHR) data. Finally, we analyzed the potential mechanisms of action of ketamine in the context of ATSUD.</p></sec><sec id="S3"><title>Participants and Measurements:</title><p id="P5">ATSUD patients who received anesthesia (N=3,663) or were diagnosed with depression (N=4,328) between January 2019 and June 2022. The outcome measure was the diagnosis of ATSUD remission within one year of the drug prescription.</p></sec><sec id="S4"><title>Findings:</title><p id="P6">Ketamine for anesthesia in ATSUD patients was associated with greater ATSUD remission compared with other anesthetics: hazard ratio (HR) = 1.58, 95% confidence interval (CI) = 1.15&#8211;2.17. Similar results were found for ATSUD patients with depression when comparing ketamine with antidepressants and bupropion/mirtazapine with HRs of 1.51 (95% CI: 1.14&#8211;2.01) and 1.68 (95% CI: 1.18&#8211;2.38), respectively. Functional analyses demonstrated that ketamine targets several ATSUD-associated pathways including neuroactive ligand-receptor interaction and amphetamine addiction.</p></sec><sec id="S5"><title>Conclusions:</title><p id="P7">There appears to be an association between clinician-prescribed ketamine and higher remission rates in patients with amphetamine-type stimulant use disorders.</p></sec></abstract><kwd-group><kwd>amphetamine-type stimulant use disorder</kwd><kwd>drug repurposing</kwd><kwd>ketamine</kwd><kwd>artificial intelligence</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-exception-type</meta-name><meta-value>EMBARGO</meta-value></custom-meta><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>4</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>no</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>